Hims & Hers Health (HIMS) Stock Price, Chart, Company Profile & AI Analysis
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss... Show more
Why Hims & Hers Health (HIMS) Stock Is Up +12% in the Last 30 Days
Key Takeaways
- HIMS shares climbed roughly 12% over the past 30 days, rising from about $27.51 at the September 11, 2026 close to $30.92 at the October 9, 2026 close.
- The advance reflects a rebound from a late-July selloff that pushed the stock to a low of $25.00 after an FTC lawsuit and a mixed second-quarter report.
- Momentum was concentrated in a sharp +10% single-session gain on October 9 on elevated volume, alongside renewed analyst commentary and positioning ahead of third-quarter results.
- Despite the rally, the stock remains roughly 10% below its mid-July level, underscoring persistent margin and regulatory concerns.
Hims & Hers Health (HIMS) Company Overview and Market Position
Hims & Hers Health, Inc. is a San Francisco-based, multi-specialty telehealth platform founded in 2017. The company connects consumers to licensed healthcare professionals and offers subscription-based access to treatments across sexual health, dermatology, mental health, hair loss, weight management, and a growing roster of newer specialties such as testosterone therapy. It sells both prescription and over-the-counter products under its Hims and Hers brands, with a direct-to-consumer, largely recurring-revenue model.
The company reported nearly 2.9 million subscribers in the second quarter of 2026 and has expanded internationally through its acquisition of Eucalyptus, which added operations in Australia, the United Kingdom, and Germany. Investors follow HIMS closely because of its rapid revenue growth, its push into branded GLP-1 weight-loss medications, and its stated ambition to embed artificial intelligence across its care platform.
Hims & Hers Health (HIMS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, HIMS moved from a September 11, 2026 closing price of $27.51 to $30.92 at the October 9 close, a gain of about 12%. The period was characterized by volatility, with the stock trading largely between $27 and $31 before a decisive +10% single-day advance on October 9 that lifted shares back above $30.
The broader quarterly picture is more mixed. In mid-July, the stock traded in the mid-$30s before falling sharply to a low of $25.00 on July 29. From that level, shares recovered in stages into the upper-$20s and low-$30s. Measured from its mid-July level, HIMS is still down roughly 10%, meaning the recent 30-day rebound has only partially unwound the prior quarter's decline.
What Drove HIMS Stock Price in the Last 30 Days
The 30-day advance was driven less by a single catalyst than by a combination of recovery sentiment, analyst activity, and repositioning ahead of earnings. On October 7, 2026, the company announced the appointment of Jon Franklin as chief accounting officer, a move framed by investors as an effort to strengthen financial oversight amid ongoing regulatory and billing scrutiny.
On October 8, Truist Securities reiterated a Hold rating with a $32 price target, citing proprietary credit-card data showing that third-quarter GLP-1 billing rose about 22% quarter over quarter, even as September billing declined month over month. The note highlighted both continued demand for branded weight-loss treatments and lingering questions about momentum. The stock then rebounded 10% on October 9 on volume well above its one-month average, a move market observers attributed to repositioning ahead of the company's next quarterly report rather than a single headline event.
What Drove HIMS Stock Performance Over the Last Quarter
The quarterly decline traces back to two events in late July and early August. On July 29, the U.S. Federal Trade Commission filed a lawsuit alleging that the company shared sensitive health data with third-party platforms and that its billing and cancellation practices were misleading, sending shares toward $25. Then, on August 10, the company reported second-quarter results that were strong on revenue but disappointing on profitability: revenue rose 38% year over year to $753.2 million, but gross margin fell to 64% from 76% a year earlier, and the company posted a wider-than-expected loss as it absorbed acquisition, restructuring, and legal costs.
The quarter's larger narrative has been the company's transition away from compounded GLP-1 medications toward branded, FDA-approved weight-loss treatments, a shift accelerated by its settlement with Novo Nordisk (NVO). Management raised full-year 2026 revenue guidance to $3.1 billion to $3.3 billion, but lower gross margins and elevated expenses left Wall Street divided on whether rapid growth can translate into sustainable profitability.
Trending AI Robots
For traders seeking a systematic approach to names like HIMS, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The bots vary widely in strategy, holding timeframe, and performance metrics, giving users a way to compare automated approaches across different market conditions. The page serves as a discovery tool for those interested in data-driven, rules-based trading rather than discretionary decisions.
HIMS Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the company's third-quarter earnings report, expected in early November 2026. Investors will focus on whether revenue growth continues near the high end of guidance, whether gross margin stabilizes after several quarters of compression, and whether the branded GLP-1 transition shows signs of improving unit economics.
Other factors to monitor include the outcome and any financial impact of the FTC litigation, the pace of international expansion through Eucalyptus, the return on the company's AI investments, and regulatory developments affecting peptide-based and compounded treatments. Analyst sentiment remains broadly cautious, with a consensus rating of Hold and price targets clustered around the low $30s, reflecting the market's wait-and-see posture on profitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
HIMS in +6.27% Uptrend, advancing for three consecutive days on October 29, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HIMS advanced for three days, in 241 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 51 of 61 cases where HIMS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 65 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
HIMS broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for HIMS entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.928) is normal, around the industry mean (8.329). P/E Ratio (-44.645) is within average values for comparable stocks, (-1.568). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 74 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric